CAR T-Cell Therapy for Blood Cancer Rarely Linked to Other Cancers: Stanford Medicine Study

Patients receiving chimeric antigen receptor T-cell (CAR-T) therapy to treat blood cancer have a low risk of developing additional blood cancers from such treatments, according to a Stanford Medicine study published Thursday in the New England Journal of Medicine (NEJM). CAR-T therapy is a type of cancer therapy for blood cancers that do not respond well to standard treatments. T immune cells are extracted from patients, genetically modified to make them better cancer fighters, and then returned to the patient’s body. The treatment has a 76 percent remission rate, according to the study. Some of the earliest trial patients have been in remission for a decade or more, and over 30,000 U.S. patients have been treated with the therapy....